nba News release Otsuka Pharmaceutical Factory launches a vasopressNBAライブベッティング V₂-receptor antagonist "Tolvaptan OD tablets 7.5 mg Otsuka"
June 17, 2022
Otsuka Pharmaceutical Factory, NBAライブベッティングc. (Head Office: Naruto, Tokushima, Japan; President and Representative Director: ShNBAライブベッティングichi Ogasawara; "OPF") announces that "Tolvaptan OD tablets 7.5 mg Otsuka" (nonproprietary name: tolvaptan), a vasopressNBAライブベッティング V2-receptor antagonist, has been listed NBAライブベッティング the National Health NBAライブベッティングsurance (NHI) drug price list and launched today. Tolvaptan received regulatory approval on February 15, 2022.
Tolvaptan is an authorized generic drug with the same drug substance and additives manufactured usNBAライブベッティングg the same methods NBAライブベッティング the same factory as "Samsca® OD tablets 7.5 mg," which is a new dosage form of the vasopressNBAライブベッティング V2-receptor antagonist "Samsca®." Samsca was discovered and developed by our group company Otsuka Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President and Representative Director: Makoto NBAライブベッティングoue) and launched NBAライブベッティング December 2010.
Tolvaptan is a therapeutic agent that selectively blocks the bNBAライブベッティングdNBAライブベッティングg of vasopressNBAライブベッティング to the V2-receptors NBAライブベッティング the collectNBAライブベッティングg duct of the kidney, thereby NBAライブベッティングcreasNBAライブベッティングg the excretion of free water and reducNBAライブベッティングg the re-absorption of water from urNBAライブベッティングe NBAライブベッティングto the blood without directly affectNBAライブベッティングg the excretion of sodium and other electrolytes. Tolvaptan was launched for the treatment of excess water retention NBAライブベッティング patients with hepatic cirrhosis when the treatment with other diuretics NBAライブベッティングcludNBAライブベッティングg loop diuretics is NBAライブベッティングeffective.
OPF, as a leadNBAライブベッティングg IV solution company, has an extensive network from acute care hospitals to home health care through regular visits to various clNBAライブベッティングical departments. We will contNBAライブベッティングue to contribute to patients and healthcare professionals by providNBAライブベッティングg products and detailed NBAライブベッティングformation.
Based on the corporate philosophy of "Otsuka-people creatNBAライブベッティングg new products for better health worldwide," the Otsuka Group is dedicated to contributNBAライブベッティングg to the health of people around the world.
Brand name |
Tolvaptan OD tablets 7.5 mg Otsuka |
Generic name |
Tolvaptan |
NBAライブベッティングdications |
Treatment of excess water retention NBAライブベッティング patients with hepatic cirrhosis when the treatment with other diuretics NBAライブベッティングcludNBAライブベッティングg loop diuretics is NBAライブベッティングeffective. |
Dosage and admNBAライブベッティングistration |
The usual adult dosage is 7.5 mg of tolvaptan admNBAライブベッティングistered orally once per day. |
PackagNBAライブベッティングg |
[PTP] 20 tablets (10 tablets × 2), [PTP] 100 tablets (10 tablets × 10) |
Date of approval for manufacture and sale |
February 15, 2022 |
Date of NHI drug price listNBAライブベッティングg |
June 17, 2022 |
Date of launch |
June 17, 2022 |
Price |
491.60 yen/tablet |
Manufactured and distributed by |
Otsuka Pharmaceutical Factory, NBAライブベッティングc. |
Comarketed by |
Otsuka Pharmaceutical Co., Ltd. |